SynthesisWorld journal of surgical oncology2025
Pan-immune-inflammation value in lung cancer: prognostic significance and implications for therapeutic guidance - a systematic review and meta-analysis.
Synthesis in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prognostic value of the pretreatment pan-immune-inflammation value in patients with head and neck squamous cell carcinoma: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Pooled it
- Effects of laparoscopic splenectomy and azygoportal disconnection on immune remodeling in cirrhosis patients with portal hypertension bleeding: a 1-year prospective study.Surgical endoscopy · 2026Article
- Prognostic value of perioperative inflammatory biomarkers in patients undergoing surgical resection for non-small cell lung cancer.Journal of thoracic disease · 2026Article
- Preoperative Lactate Dehydrogenase-to-Albumin Ratio as a Tumor-Host Biomarker of Early Recurrence and Survival in Resected Pulmonary Neuroendocrine Carcinomas: A Multicenter Observational Cohort Study.Medicina (Kaunas, Lithuania) · 2026Observational
- Pretreatment Lactate Dehydrogenase-to-Albumin Ratio and Clinical Outcomes in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study.Journal of clinical medicine · 2026Article
- The Prognostic Significance of the Systemic Inflammation Response Index (SIRI) and HALP Score in Hodgkin's Lymphoma.Diagnostics (Basel, Switzerland) · 2026Article
- Revisiting PIV in lung cancer: bridging prognostic insights with clinical applicability.World journal of surgical oncology · 2026Article
- Pan-immune-inflammation value predicts 2-year recurrence after chemoradiotherapy in nasopharyngeal carcinoma.Frontiers in medicine · 2026Article
- Combined immunoscore and pan-immune inflammation value associated with pathological response and survival outcomes in esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy.International journal of surgery (London, England) · 2026Article
- Association of Preoperative Pan-Immune-Inflammation Value with Adverse Pathology and Oncological Outcomes Following Radical Prostatectomy: A Single-Center Retrospective Study.International journal of medical sciences · 2026Article
- Pretreatment Pan-Immune-Inflammation Value and Corrected Prognostic Nutritional Index for 24-Month Recurrence Risk Stratification After Neoadjuvant Chemotherapy and Surgery in Stage III Endometrial Cancer.International journal of women's health · 2026Article
- Pan-immune-inflammation value as an independent prognostic marker in patients with brain metastases.Frontiers in oncology · 2025Article
- A Multicenter Study of Systemic Inflammatory Biomarkers for Prognostic Evaluation in iCCA Patients.Journal of inflammation research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLung cancer is a major global health issue with high variability in incidence and mortality. However, reliable predictive biomarkers for lung cancer prognosis remain lacking. The pan-immune-inflammation value (PIV) has emerged as a promising prognostic tool by reflecting systemic immune and inflammatory responses.
methodsA meta-analysis was performed using data from Web of Science, PubMed, and PMC up to April 2025. Clinical studies involving lung cancer patients reporting hazard ratios (HRs) and 95% confidence intervals (CIs) for overall survival (OS) and progression-free survival (PFS) were included.
resultsA total of eleven articles met the inclusion criteria, encompassing 3,290 lung cancer patients. High PIV levels were consistently associated with poorer OS (HR = 2.364, 95% CI = 2.033-2.749, P < 0.001) and PFS (HR = 1.975, 95% CI = 1.704-2.290, P < 0.001). Notably, PIV predicted both OS and PFS outcomes across various treatment strategies, including PD-1/PD-L1 inhibitor therapy (OS: HR = 2.372, 95% CI = 1.867-3.013, P < 0.001; PFS: HR = 1.830, 95% CI = 1.494-2.241, P < 0.001). Additionally, subgroup analyses showed that PIV's prognostic value remained consistent across different lung cancer types, analytical methods, PIV cutoff values, sample sizes, study regions, and follow-up durations (P < 0.001). Sensitivity analyses confirmed the stability of these findings, with minimal heterogeneity across studies.
conclusionPIV is a robust prognostic marker for lung cancer, reliably predicting both OS and PFS. It offers valuable insights across various treatment strategies, including immunotherapy, and could enhance clinical decision-making by providing a cost-effective and reliable tool for evaluating patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.